Gastrointestinal

Barrett esophagus: surveillance and management

Clinical Overview and When to Suspect Barrett Esophagus

— US/ACG criteria require both salmon-colored mucosa on endoscopy and intestinal metaplasia on histology. British guidelines accept columnar metaplasia without goblet cells, but Step 3 follows ACG.

— Length classified by Prague C&M criteria: C = circumferential extent, M = maximal extent above GEJ.

— Male sex

— Age >50

— White race

— Tobacco use (current or past)

— Central obesity (waist circumference, not BMI alone)

— First-degree relative with BE or EAC

Board pearl: A patient with >5 years of weekly heartburn who is a 50-year-old obese white male smoker is the prototypical screening candidate — recognizing this risk constellation is more often tested than the histology itself.

Step 3 management: Do not screen all GERD patients. Screening is risk-factor driven and one-time if initial EGD is negative — repeat screening only if risk profile changes substantially.

Definition: Barrett esophagus (BE) is the metaplastic replacement of the normal stratified squamous epithelium of the distal esophagus by columnar epithelium with intestinal metaplasia (goblet cells) on biopsy, extending ≥1 cm above the gastroesophageal junction (GEJ).

Pathophysiology: Chronic acid and bile reflux → mucosal injury → metaplasia → dysplasia → adenocarcinoma. Annual risk of progression to esophageal adenocarcinoma (EAC) is ~0.2–0.5%/year for nondysplastic BE.

When to suspect/screen: Chronic GERD (≥5 years) plus ≥3 additional risk factors:

Who NOT to screen: Women with GERD generally do not warrant screening unless multiple risk factors are present, given low EAC incidence.

Screening modality: Sedated upper endoscopy (EGD) is standard. Unsedated transnasal endoscopy and swallowable cell-collection devices (e.g., Cytosponge with TFF3) are emerging alternatives endorsed by ACG 2022 as acceptable.

Presentation Patterns and Key History

— Duration and frequency of reflux symptoms (≥5 years, ≥weekly is the threshold)

— Response to PPI therapy and adherence

— Nocturnal symptoms, regurgitation, chronic cough, hoarseness, dental erosions (extraesophageal GERD)

— Dysphagia, odynophagia, weight loss, anemia, hematemesis, melena — these are alarm features mandating prompt EGD regardless of age

— Family history of BE or esophageal adenocarcinoma in a first-degree relative

— Tobacco use — quantify pack-years

— Alcohol — actually not a major BE risk factor (contrast with squamous cell carcinoma)

— Diet: low fruit/vegetable intake, high processed meat

— Central adiposity — measure waist circumference

— Chronic NSAIDs/aspirin (interestingly, may reduce EAC risk)

— PPIs (chemopreventive effect debated but recommended in BE)

— Bisphosphonates, tetracyclines (pill esophagitis confounder)

Key distinction: Reflux symptoms that wane with time in a longstanding GERD patient are not reassuring — they may reflect mucosal replacement by less-sensitive columnar epithelium, not disease resolution. Worsening dysphagia in this setting is a red flag for stricture or adenocarcinoma.

Board pearl: Alarm features (dysphagia, odynophagia, GI bleed, anemia, weight loss, vomiting, age >60 with new symptoms) override screening algorithms — go straight to EGD.

Classic stem: Middle-aged or older man with longstanding GERD (heartburn, regurgitation, water brash) presenting for routine care, often with paradoxical improvement in heartburn over time as metaplastic columnar epithelium is less acid-sensitive than squamous mucosa.

Symptom history to elicit:

Risk factor history (the Step 3 checklist):

Medication history:

Protective factors to note: H. pylori infection is inversely associated with BE/EAC — eradication in BE patients is still indicated when present for ulcer/cancer prevention, but the association is a favorite test point.

Physical Exam Findings (and Risk Phenotype Assessment)

— Central obesity is the key BE-relevant adiposity pattern; measure waist circumference (>102 cm men, >88 cm women) and waist-to-hip ratio rather than relying on BMI alone.

— Visceral fat drives intra-abdominal pressure → reflux → metaplasia.

— Dental erosions (lingual surfaces of upper teeth) suggest chronic acid exposure

— Halitosis, erythematous posterior pharynx, "cobblestoning" with laryngopharyngeal reflux

— Usually unremarkable in uncomplicated BE

— Epigastric tenderness is nonspecific

— A palpable mass, supraclavicular (Virchow) node, or hepatomegaly suggests advanced adenocarcinoma — escalate workup immediately

— Conjunctival pallor (anemia from chronic occult blood loss or tumor)

— Cachexia, temporal wasting (esophageal malignancy)

— Lymphadenopathy: left supraclavicular (Virchow), periumbilical (Sister Mary Joseph) — though more classic for gastric, can occur in distal esophageal/GEJ adenocarcinoma

Step 3 management: In an outpatient BE follow-up visit, track weight, waist circumference, and blood pressure at each visit — weight loss counseling is part of the longitudinal management plan, not an afterthought.

Board pearl: A new iron-deficiency anemia in a man with known BE warrants prompt EGD to evaluate for ulcerated dysplastic lesions or adenocarcinoma, not empiric iron therapy alone.

General principle: Barrett esophagus has no specific physical exam findings. The exam supports risk stratification and identifies complications rather than diagnosing BE itself.

Body habitus and anthropometrics:

Oropharyngeal exam:

Pulmonary: Wheezing or chronic cough may reflect reflux-induced bronchospasm or microaspiration; consider in asthma poorly controlled despite standard therapy.

Abdominal exam:

Signs of complications/advanced disease:

Hemodynamic assessment: Relevant only if presenting with upper GI bleeding from esophagitis, ulcerated BE, or tumor — assess for tachycardia, orthostasis, and resuscitate before endoscopy.

Diagnostic Workup — Initial Endoscopic and Histologic Evaluation

— Adequate insufflation and mucosal cleansing

— Careful inspection of the squamocolumnar junction (Z-line) and gastroesophageal junction (top of gastric folds)

— Document Prague C&M classification (e.g., C2M5 = 2 cm circumferential, 5 cm maximal tongue)

— Inspect for visible lesions: nodules, ulcers, strictures — these markedly raise risk of dysplasia/cancer

— 4-quadrant biopsies every 2 cm of BE segment (every 1 cm if known or suspected dysplasia)

— Targeted biopsies of any visible lesion FIRST, in separate jars, before random biopsies

— Minimum 8 biopsies recommended to maximize intestinal metaplasia yield

— Confirm intestinal metaplasia with goblet cells (Alcian blue stain at pH 2.5 highlights them)

— Dysplasia graded: negative, indefinite, low-grade (LGD), high-grade (HGD), intramucosal carcinoma

— Two expert GI pathologists should confirm any dysplasia diagnosis (high interobserver variability)

Key distinction: "Irregular Z-line" (<1 cm of columnar mucosa above GEJ) is NOT Barrett esophagus and should not be biopsied or surveyed — a high-yield Step 3 trap. Calling it BE creates unnecessary lifelong surveillance and insurance/anxiety burden.

CCS pearl: When ordering the index EGD, write "EGD with Seattle protocol biopsies for surveillance/diagnosis of Barrett esophagus" — generic "EGD with biopsy" may not capture proper sampling.

Index EGD is the diagnostic cornerstone. Requirements for a quality exam:

Biopsy protocol — Seattle protocol:

Histology interpretation:

Adjunct imaging chromoendoscopy: Narrow-band imaging (NBI), acetic acid chromoendoscopy improve detection of dysplastic foci; standard of care at expert centers.

Labs to obtain at diagnosis: CBC (anemia), basic metabolic panel; no specific serum biomarker is established. H. pylori testing if not previously done.

Diagnostic Workup — Confirmation, Staging, and Advanced Studies

— Any dysplasia (LGD or HGD) → expert GI pathologist confirmation required before acting

— "Indefinite for dysplasia" → optimize PPI (twice daily × 3–6 months) to reduce inflammation-related atypia, then repeat EGD with biopsies

— Nondysplastic BE confirmed → enter surveillance program

— LGD confirmed → discuss endoscopic eradication therapy (EET) vs. surveillance every 6–12 months

— HGD or intramucosal carcinoma → proceed to EET and staging

— Endoscopic mucosal resection (EMR) of any visible lesion provides definitive T-staging (mucosa vs. submucosa) and is both diagnostic and therapeutic

— Endoscopic ultrasound (EUS) is not routinely recommended for HGD or T1a disease; reserve for suspected deeper invasion or nodal disease

— CT chest/abdomen with contrast and PET-CT for invasive adenocarcinoma (≥T1b) to assess metastases

— TissueCypher (multimarker tissue test) risk-stratifies progression in nondysplastic and LGD BE

— p53 immunohistochemistry — abnormal staining supports true dysplasia; endorsed by BSG and increasingly by ACG

Board pearl: EMR changes management in ~50% of patients diagnosed with HGD on forceps biopsy — submucosal invasion upgrades them to surgical/oncologic pathways. Always resect visible lesions before committing to ablation-only therapy.

Step 3 management: Do not order EUS for flat HGD without a visible nodule — it adds cost and rarely changes management. Order EMR of nodular lesions instead.

Confirming dysplasia:

Repeat EGD timing after initial diagnosis:

Staging for HGD / suspected cancer:

Molecular/biomarker testing (emerging, not yet universal):

Wide-area transepithelial sampling (WATS-3D) with computer-assisted analysis as an adjunct to Seattle protocol — improves dysplasia detection.

Risk Stratification and Management Logic by Histology

— Short segment (<3 cm): surveillance EGD every 5 years

— Long segment (≥3 cm): surveillance EGD every 3 years

— PPI once daily for symptom and chemoprevention rationale

— Optimize PPI BID × 3–6 months → repeat EGD with Seattle biopsies

— If persistent → manage as LGD

— Preferred: endoscopic eradication therapy (typically radiofrequency ablation, RFA)

— Alternative: surveillance every 6 months × 1 year, then annually

— Shared decision-making — discuss progression risk (~10–13%/year to HGD/EAC in confirmed LGD)

— EET is standard of care — EMR of any visible lesion + RFA of remaining BE

— Esophagectomy reserved for multifocal disease, failed endoscopic therapy, or submucosal invasion

— EMR (curative if margins negative, well-differentiated, no lymphovascular invasion)

— Followed by ablation of residual BE

— Risk of nodal metastasis 20–30% → multidisciplinary evaluation for esophagectomy ± neoadjuvant therapy

Key distinction: Surveillance intervals are based on the highest grade of dysplasia ever found, not the current biopsy — a patient with previously confirmed LGD does not return to 3- or 5-year intervals after one negative exam.

Board pearl: Endpoint of EET is complete eradication of intestinal metaplasia (CE-IM) — not just dysplasia. Residual BE harbors ongoing cancer risk and requires continued ablation sessions until CE-IM achieved.

Management is dictated by the worst histologic finding, segment length, and visible lesions. Build a mental decision tree:

Nondysplastic BE (NDBE):

Indefinite for dysplasia:

Low-grade dysplasia (LGD), expert-confirmed:

High-grade dysplasia (HGD):

Intramucosal carcinoma (T1a):

Submucosal invasion (T1b):

Pharmacotherapy — PPIs and Adjunctive Therapy

— Once-daily PPI for all BE patients regardless of symptoms — reduces inflammation and may decrease progression risk

— Twice-daily PPI for symptomatic GERD, esophagitis, or after EET to optimize healing

— Take 30–60 minutes before breakfast (and dinner for BID dosing) — empty-stomach activation is essential

— Possible associations: B12 deficiency, hypomagnesemia, C. difficile infection, community-acquired pneumonia, CKD, osteoporotic fracture, dementia

— Most evidence is observational; do not discontinue PPIs in BE patients out of concern for these associations — benefits outweigh risks

— Monitor magnesium and B12 in patients on PPI >2 years if symptoms suggest deficiency

— AspECT trial showed high-dose PPI + aspirin reduced all-cause mortality and EAC in BE

— Consider low-dose aspirin (81 mg) in BE patients who also have cardiovascular indications — do not start solely for BE without CV risk

Step 3 management: A patient on long-term PPI for BE who develops fatigue and paresthesias — check B12 and magnesium before changing therapy. Do not stop the PPI.

Board pearl: Anti-reflux surgery (Nissen fundoplication) controls symptoms and reduces reflux but has not been shown to reduce BE progression to EAC compared with PPI — reserve for refractory GERD or PPI-intolerant patients, not for cancer prevention.

Proton pump inhibitors (PPIs) are foundational:

Agent selection: Omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole — comparable efficacy. Use the lowest effective dose long-term.

PPI long-term safety counseling (commonly tested):

Aspirin chemoprevention:

H2 blockers, antacids, alginates: Adjunctive for breakthrough symptoms; insufficient acid suppression as monotherapy.

Avoid/limit: Smoking, alcohol excess, late-evening meals, recumbent position post-meals, tight-waisted clothing.

Endoscopic Eradication Therapy and Surgical Management

— Indications: Any visible nodule, mucosal irregularity, or area of suspected dysplasia/cancer

— Provides definitive histologic staging (depth, margins, lymphovascular invasion, differentiation)

— Curative for T1a if: well/moderately differentiated, no LVI, negative deep margin, ≤2 cm

— ESD preferred for larger lesions, suspected superficial submucosal invasion

— First-line ablation modality after resection of visible lesions

— Sessions every 2–3 months until CE-IM achieved (typically 2–4 sessions)

— Cryotherapy (liquid nitrogen or CO₂) is an alternative, useful for refractory or residual disease

— After CE-IM in HGD/IMC: EGD at 3, 6, 12 months, then annually

— After CE-IM in LGD: EGD at 1 and 3 years, then every 2 years

— Biopsy GEJ and any visible columnar mucosa at every surveillance

— Reserved for: T1b with high-risk features, multifocal HGD not amenable to endoscopic therapy, failed EET, or patient preference

— Significant morbidity (~30–50%) and mortality (~2–5% at high-volume centers) — refer to high-volume surgical centers (volume-outcome relationship is a Step 3 systems-of-care point)

CCS pearl: When EMR pathology returns T1a, well-differentiated, negative margins, no LVI → continue with RFA to eradicate residual BE; do NOT reflexively refer to surgery.

Board pearl: Strictures occur in ~5–10% after RFA; managed with endoscopic dilation. Counsel patients pre-procedure.

Endoscopic eradication therapy (EET) is the standard for dysplastic BE and T1a adenocarcinoma. Two pillars:

Endoscopic resection (EMR or ESD):

Mucosal ablation — Radiofrequency ablation (RFA):

Post-EET surveillance schedule:

Esophagectomy:

Neoadjuvant chemoradiation for locally advanced (≥T2 or node-positive) adenocarcinoma (CROSS regimen).

Special Populations — Elderly and Renal/Hepatic Impairment

— Balance projected life expectancy against the slow natural history of BE progression

— De-escalate or discontinue surveillance when life expectancy <5–10 years or competing comorbidities dominate prognosis

— ACG explicitly endorses cessation of surveillance in patients unlikely to benefit from EET if cancer were found

— Document shared decision-making conversations with patients and families

— Use propofol with anesthesia support for high-risk patients

— Aspiration risk elevated — consider endotracheal intubation for prolonged ablation sessions

— Antiplatelet/anticoagulant management per ASGE periprocedural guidelines (hold per bleeding risk of procedure)

— PPIs metabolized hepatically — no dose adjustment for CKD

— Monitor magnesium more frequently (CKD + PPI synergistically risk hypomagnesemia)

— Bowel prep not required for EGD, but contrast for staging CT may be limited in advanced CKD

— Reduce PPI dose in severe hepatic impairment (esomeprazole max 20 mg/day in Child-Pugh C)

— Portal hypertension with varices complicates surveillance — coordinate with hepatology before ablation; varices increase bleeding risk

— Avoid NSAIDs/aspirin chemoprevention in advanced cirrhosis

Step 3 management: In a 78-year-old with NDBE, advanced CHF, and CKD stage 4, the correct answer is often discontinue surveillance with documented goals-of-care discussion — not "continue EGD every 5 years."

Key distinction: Age alone does not stop surveillance — functional status and life expectancy drive the decision. A 78-year-old marathon runner is different from a 78-year-old with advanced dementia.

Elderly patients (≥75 years):

Frailty assessment: Use clinical frailty scale, functional status, and cognitive evaluation rather than chronologic age alone. A robust 80-year-old may benefit from EET; a frail 70-year-old may not.

Sedation considerations:

Renal impairment:

Hepatic impairment:

Special Populations — Pregnancy, Younger Patients, and Family Screening

— BE itself does not flare in pregnancy, but GERD frequently worsens due to progesterone-mediated LES relaxation and mechanical pressure

— PPIs are generally safe in pregnancy — most are Category B; omeprazole previously Category C but considered safe in clinical practice

— Avoid elective EGD or ablation during pregnancy; defer surveillance unless alarm symptoms arise

— If urgent EGD needed → second trimester preferred, left lateral position, fetal monitoring per gestational age

— BE is uncommon — when diagnosed, evaluate carefully for family history of BE/EAC; consider genetic susceptibility (no single confirmed gene, but familial clustering is recognized)

— Long anticipated horizon → EET threshold is lower for any confirmed dysplasia

— Counsel on lifestyle, weight management, smoking cessation aggressively given decades of potential exposure

— Screen first-degree relatives of patients with EAC or BE with HGD/cancer beginning at age 50 (or 10 years before the youngest affected relative)

— A single negative EGD is generally sufficient unless symptoms develop

— BE is rare in children; when present, usually associated with severe GERD, neurologic impairment, repaired esophageal atresia, or cystic fibrosis

— Refer to pediatric GI; surveillance intervals not well-defined — typically every 3–5 years

— Weight loss (5–10% of body weight) reduces reflux and may slow BE progression

— Bariatric surgery: Roux-en-Y gastric bypass preferred over sleeve gastrectomy in BE patients because sleeve worsens reflux

Board pearl: A 35-year-old with new BE on EGD — ask about a father or brother with esophageal adenocarcinoma before assuming sporadic disease, and consider lower threshold for dysplasia surveillance.

Pregnancy:

Younger patients (<40 years):

Family screening (familial BE/EAC):

Pediatric considerations:

Obesity management:

Complications and Adverse Outcomes

— Annual risk: NDBE ~0.2–0.5%, LGD ~0.7%, HGD ~7% per year

— Once invasive, 5-year survival drops sharply (<20% for advanced disease vs. >85% for T1a treated endoscopically)

— Early detection through surveillance is the entire point of the program

— Esophageal stricture (5–10% after RFA, higher after circumferential EMR) — present with dysphagia; treat with endoscopic dilation

— Bleeding (1–3%) — usually self-limited; manage endoscopically

— Perforation (<1%) — surgical emergency; chest pain, subcutaneous emphysema, mediastinal air on imaging

— Chest pain, odynophagia, low-grade fever post-procedure — common and self-limited, manage with analgesia, sucralfate, viscous lidocaine

— Residual intestinal metaplasia under neosquamous epithelium after ablation

— Can still progress to cancer — rationale for continued surveillance even after CE-IM

— ~20–30% over 5 years, often at the GEJ

— Underscores need for continued surveillance even with successful eradication

Step 3 management: Post-RFA patient returns at 6 weeks with progressive dysphagia to solids → most likely benign stricture; next step is EGD with dilation, not CT or barium swallow.

Board pearl: New solid-food dysphagia in a BE patient who has NOT had recent procedures is cancer until proven otherwise — urgent EGD.

Progression to esophageal adenocarcinoma (EAC):

Procedure-related complications of EET:

Buried metaplasia / subsquamous intestinal metaplasia:

PPI-related long-term issues (already covered): B12, magnesium, fracture risk, C. difficile, possible CKD progression — monitor but do not stop PPI for BE.

Recurrence of intestinal metaplasia after CE-IM:

Psychological burden: Cancer-related anxiety, surveillance fatigue, insurance/billing concerns — address proactively.

When to Escalate Care — Consultation and Inpatient Triage

— New alarm symptoms in known BE: dysphagia, odynophagia, weight loss, GI bleeding, anemia

— Confirmed LGD or HGD on biopsy

— Visible nodule, ulcer, or mass in BE segment

— "Indefinite for dysplasia" not resolving with optimized PPI

— Any dysplasia requiring EET — outcomes are operator/center-dependent

— Long-segment BE (≥3 cm) with planned ablation

— Failed prior EET

— Consideration of esophagectomy

— Acute upper GI bleed from BE, esophagitis, or tumor — IV PPI, transfusion, urgent EGD per Glasgow-Blatchford/AIMS65 risk

— Post-procedural perforation — NPO, broad-spectrum antibiotics (ceftriaxone + metronidazole), surgical consultation, contrast esophagram or CT with oral contrast

— Severe odynophagia preventing oral intake post-EET → IV hydration, pain control, evaluate for stricture/perforation

CCS pearl: For acute upper GI bleed in BE → orders include two large-bore IVs, type and crossmatch, IV pantoprazole 80 mg bolus then 8 mg/hr drip, NPO, GI consult for urgent EGD within 24 hours, transfuse to Hgb >7 (>8 if cardiac disease).

Step 3 management: A patient 24 hours post-RFA with fever, chest pain, and crepitus → STAT chest CT with oral contrast, surgical consult, NPO, IV antibiotics — do NOT delay imaging for repeat EGD.

Most BE care is outpatient. Escalation triggers fall into three categories: diagnostic urgency, procedural complications, and advanced disease.

Urgent GI referral / expedited EGD (outpatient, days):

Referral to high-volume Barrett's center:

Inpatient admission indicated:

Multidisciplinary tumor board: Required for any invasive adenocarcinoma — surgical oncology, medical oncology, radiation oncology, pathology, radiology, GI.

Hospice/palliative care referral: Advanced unresectable EAC with limited prognosis — early integration improves quality of life and may improve survival.

Key Differentials — Other Esophageal Mucosal Conditions

Within the spectrum of esophageal mucosal disease, BE must be distinguished from:

— Linear or confluent erosions of distal squamous mucosa

— Caused by acid reflux; reverses with PPI therapy

— Severe esophagitis can mask underlying BE — repeat EGD after 8–12 weeks of high-dose PPI to assess for residual BE

— NOT Barrett esophagus by US criteria

— Do not biopsy, do not enter surveillance

— Common Step 3 trap — selecting "begin surveillance every 5 years" is wrong

— Young adults, atopy history, solid food dysphagia, food impaction

— Endoscopy: rings, furrows, white exudates, narrow-caliber esophagus

— Biopsy: ≥15 eosinophils/HPF

— Treat with topical steroids (swallowed fluticasone/budesonide), dietary elimination, PPI

— Tetracyclines, bisphosphonates, NSAIDs, potassium chloride

— Discrete ulcers, often mid-esophagus at aortic arch crossing

— Resolves with offending agent removal

— Candida (white plaques), HSV (small discrete ulcers), CMV (large linear ulcers)

— Biopsy and PCR-directed therapy

— Salmon-colored island in proximal esophagus near UES

— Usually incidental, no surveillance required unless symptomatic or dysplastic

Key distinction: Columnar mucosa without goblet cells in the distal esophagus is cardiac-type metaplasia — does not meet US criteria for BE and does not warrant surveillance. UK guidelines differ.

Board pearl: In severe esophagitis, defer surveillance biopsies until after 8–12 weeks of PPI — inflammation distorts histology and obscures or mimics dysplasia.

Erosive esophagitis (Los Angeles grades A–D):

Irregular Z-line / "ultra-short" columnar tongues (<1 cm):

Eosinophilic esophagitis (EoE):

Pill esophagitis:

Infectious esophagitis (immunocompromised hosts):

Caustic / radiation esophagitis: Historical clues drive diagnosis.

Gastric inlet patch (heterotopic gastric mucosa):

Key Differentials — Other Causes of Dysphagia, Bleeding, or Weight Loss

Beyond mucosal mimics, consider the broader DDx that triggers the same workup:

— Upper/mid esophagus more common

— Risk factors: tobacco, alcohol, hot beverages, achalasia, caustic injury, HPV (some)

— Contrast with BE-associated adenocarcinoma: distal esophagus/GEJ, obesity, GERD, white men

— Progressive dysphagia to both solids and liquids, regurgitation of undigested food

— Manometry: absent peristalsis, failed LES relaxation

— Increases SCC risk long-term — endoscopic surveillance debated

— Slow progressive solid dysphagia in longstanding GERD

— Treat with PPI + endoscopic dilation

Step 3 management: New solid-food dysphagia with weight loss in a 65-year-old smoker with GERD history → EGD first, not barium swallow. EGD allows biopsy and intervention; barium is appropriate only for suspected proximal lesions, motility disorders, or when EGD is unsafe.

Board pearl: Adenocarcinoma rising, SCC falling in US epidemiology — driven by obesity/GERD and decline in smoking. A "distal esophageal mass in a white obese man" is adenocarcinoma until proven otherwise; "mid-esophageal mass in a thin smoker/drinker" is SCC.

Esophageal squamous cell carcinoma (SCC):

Achalasia:

Esophageal stricture (peptic):

Schatzki ring: Intermittent solid-food dysphagia/impaction; treat with dilation.

Esophageal motility disorders: Diffuse esophageal spasm, jackhammer, ineffective motility — manometry-based diagnosis.

Zenker diverticulum: Oropharyngeal dysphagia, regurgitation, halitosis, neck mass — barium swallow.

Gastric/GEJ adenocarcinoma: Overlaps with distal EAC; Siewert classification guides management.

Peptic ulcer disease, varices, Mallory-Weiss tear, Dieulafoy lesion: Other UGI bleed sources to consider alongside BE-related bleeding.

Non-GI causes of weight loss and anemia: Malignancy (colon, pancreas), hyperthyroidism, malabsorption — do not anchor on BE if pattern doesn't fit.

Secondary Prevention and Long-Term Management Plan

— Once-daily PPI indefinitely for all BE patients

— Step up to BID if symptomatic, esophagitis present, or post-EET healing phase

— Reassess dose annually — use lowest effective dose

— Weight loss to BMI <25 and waist circumference reduction — most impactful modifiable risk factor

— Smoking cessation — refer to pharmacotherapy (varenicline, NRT) + counseling

— Alcohol moderation

— Elevate head of bed 6–8 inches; avoid meals within 3 hours of recumbency

— Avoid trigger foods empirically only if symptomatic (chocolate, mint, fatty, spicy, citrus, caffeine)

— Low-dose aspirin (81 mg daily) considered in BE patients with concurrent cardiovascular indications — do not initiate solely for BE

— Statins associated with reduced EAC risk in observational studies; use per ASCVD criteria

— Confirm patient understands interval and rationale

— Track in registry / EHR reminders to prevent loss to follow-up — a transitions-of-care vulnerability

— Coordinate EGD timing with other procedures (e.g., screening colonoscopy) when feasible

— Update vaccinations, screening labs

Step 3 management: At every BE follow-up, document PPI adherence, weight/waist, smoking status, surveillance interval, and next EGD date — these are the longitudinal anchors graded on real-world quality metrics and tested on Step 3.

Board pearl: Anti-reflux surgery does not replace surveillance — patients with Nissen fundoplication and BE still require scheduled EGDs.

Acid suppression (cornerstone):

Lifestyle modifications (longitudinal counseling):

Chemoprevention:

Surveillance program enrollment:

Health maintenance integration:

Patient education resources: ACG and AGA patient handouts, support groups for those with high-risk BE or post-esophagectomy.

Address modifiable comorbidities: OSA (worsens reflux), diabetes (associated with BE), metabolic syndrome.

Follow-Up, Monitoring Parameters, and Counseling

— NDBE, short segment (<3 cm): EGD every 5 years

— NDBE, long segment (≥3 cm): EGD every 3 years

— Indefinite for dysplasia: PPI BID × 3–6 months, then repeat EGD

— LGD (untreated): every 6 months × 1 year, then annually

— LGD after CE-IM: EGD at 1 year, 3 years, then every 2 years

— HGD/IMC after CE-IM: EGD at 3, 6, 12 months, then annually

— Reassess Prague C&M

— Targeted biopsies of any visible lesion + Seattle protocol

— Inspect for nodules, ulcers, strictures

— B12 every 1–2 years if on PPI >2 years and any suggestive symptoms

— Magnesium with each comprehensive metabolic panel

— Bone density per general guidelines, not specifically for PPI use

— Symptom changes — alarm features prompt earlier EGD

— Adherence to PPI and lifestyle measures

— Weight, BP, waist circumference

— Smoking cessation reinforcement

— Cancer risk in context — many patients overestimate it; provide realistic figures (NDBE annual EAC risk ~0.2–0.5%)

— Symptom monitoring for dysphagia (stricture)

— Repeat ablation sessions until CE-IM

— Continue indefinite surveillance even after CE-IM (recurrence risk)

Step 3 management: A patient with NDBE missed their scheduled 3-year EGD and presents 5 years later — do not extend further. Schedule EGD now with Seattle biopsies and reset the interval based on findings.

Board pearl: Quality metric: proper Seattle protocol biopsies correlate strongly with dysplasia detection — incomplete sampling is a leading cause of "missed" interval cancers.

Surveillance intervals (memorize the grid):

At each surveillance EGD:

Lab monitoring on chronic PPI:

Counseling at each visit:

Post-EET specifically:

Ethical, Legal, and Patient Safety Considerations

— Discuss alternatives: surveillance vs. ablation vs. surgery

— Risks: stricture, bleeding, perforation, incomplete eradication, recurrence

— Benefits: cancer risk reduction, organ preservation vs. esophagectomy

— For LGD specifically — patient values weigh heavily; surveillance is an acceptable alternative to ablation

— When life expectancy <5–10 years, surveillance offers little benefit

— Document the conversation explicitly — "patient understands that finding cancer would not change management given comorbidities, elects to discontinue surveillance"

— Avoid paternalistic continuation; avoid abrupt unilateral discontinuation

— BE patients are commonly lost to follow-up when changing PCPs, insurance, or geography

— Establish EHR-based surveillance reminders, patient portal alerts, and patient-held "BE passports" with diagnosis date, Prague score, last biopsy results, next due date

— When transferring care, send full pathology and Prague documentation — not just a summary

— Time-out protocols, anticoagulation management per ASGE

— Pathology specimen labeling — Seattle protocol generates many jars; mislabeling can lead to wrong-segment ablation

— Mandatory expert confirmation of dysplasia is both a quality and medicolegal safeguard

— Acting on unconfirmed LGD has led to litigation when patients undergo unnecessary EET

— Missed cancers on prior EGD or biopsy interval lapses → disclose per institutional policy and applicable state laws

Step 3 management: Before initiating EET for LGD, obtain expert pathology confirmation and document shared decision-making — failure to do either is both an ethical and medicolegal vulnerability.

Board pearl: Surveillance non-adherence is one of the most common causes of preventable BE-related cancer mortality — a system-level patient safety issue.

Informed consent for EET:

Shared decision-making in elderly/limited life expectancy:

Transitions of care — high-risk Step 3 issue:

Patient safety in sedation/endoscopy:

Pathology second opinion:

Disclosure of error:

High-Yield Associations and Rapid-Fire Clinical Facts

— NDBE <3 cm → q5 yrs

— NDBE ≥3 cm → q3 yrs

— LGD → EET preferred or q6–12 mo surveillance

— HGD/T1a → EET

Board pearl: If a stem describes a "salmon-colored mucosa extending 4 cm above the GEJ with goblet cells on biopsy" → BE, long-segment, surveillance every 3 years if nondysplastic.

Risk factor mnemonic — "WHO MAGS": White, Hiatal hernia, Obesity (central), Male, Age >50, GERD chronic, Smoking; add family history.

Prague C&M: C = circumferential, M = maximal length above GEJ. Always document both.

Seattle protocol: 4-quadrant biopsies q2 cm (q1 cm if dysplasia known/suspected), separate jars; visible lesions biopsied/resected separately FIRST.

Surveillance grid:

EAC progression risk: NDBE 0.2–0.5%/yr · LGD ~0.7%/yr · HGD ~7%/yr.

PPI timing: 30–60 min before meal; BID dosing = before breakfast and dinner.

Aspirin chemoprevention (AspECT trial): Benefit in BE when combined with high-dose PPI; use if CV indication present.

H. pylori and BE: Inverse association with EAC — but eradicate when present per standard indications.

Obesity pattern: Central (visceral) > BMI alone.

Sleeve gastrectomy worsens reflux; Roux-en-Y preferred in obese BE patients.

Irregular Z-line (<1 cm): Not BE; no surveillance.

Cardiac metaplasia (no goblet cells): Not BE by US criteria.

EAC vs. SCC US epidemiology: Adenocarcinoma rising, SCC falling.

Endpoint of EET: CE-IM (complete eradication of intestinal metaplasia), not just CE-D.

EMR for any visible nodule — both diagnostic (staging) and therapeutic.

Buried glands after RFA → rationale for continued surveillance post-CE-IM.

Stricture is the most common RFA complication (~5–10%); manage with dilation.

Nissen fundoplication controls symptoms but does NOT reduce cancer risk vs PPI.

Family screening: First-degree relatives of EAC/HGD patients starting at age 50 or 10 years before youngest affected.

Esophagectomy mortality lower at high-volume centers — volume-outcome relationship.

Board Question Stem Patterns

Board pearl: Step 3 stems often layer two decision points (e.g., screening + lifestyle, or LGD + family screening) — answer both elements in management questions.

Pattern 1 — Screening decision: 55-year-old obese white man with 10 years of weekly heartburn, smoker, father with EAC. Next step? → EGD for BE screening (one-time, risk-factor driven).

Pattern 2 — Irregular Z-line trap: EGD shows "small tongues of columnar mucosa <1 cm above GEJ." Next step? → No surveillance, no biopsy — this is not BE.

Pattern 3 — Nondysplastic BE management: 5 cm of salmon mucosa, biopsies confirm intestinal metaplasia without dysplasia. Next surveillance? → EGD in 3 years (long-segment NDBE).

Pattern 4 — Indefinite for dysplasia: Biopsy shows "indefinite for dysplasia" in setting of active esophagitis. Next step? → High-dose PPI BID × 3–6 months, then repeat EGD.

Pattern 5 — Confirmed LGD: Two expert pathologists confirm LGD. Best management? → Endoscopic eradication therapy (RFA) preferred; surveillance q6 mo is acceptable alternative.

Pattern 6 — HGD with nodule: Visible 1 cm nodule with HGD on biopsy. Next step? → EMR of nodule first (staging + therapy), then RFA of residual BE.

Pattern 7 — Post-RFA dysphagia: Solid-food dysphagia 6 weeks post-RFA. Next step? → EGD with dilation (stricture).

Pattern 8 — Alarm features: Known BE patient develops weight loss and progressive dysphagia. Next step? → Urgent EGD, regardless of last surveillance interval.

Pattern 9 — Elderly with comorbidities: 82-year-old with NDBE, advanced dementia, life expectancy <5 years. Best plan? → Discontinue surveillance after shared decision-making.

Pattern 10 — Anti-reflux surgery question: BE patient asks if Nissen fundoplication will prevent cancer. Best response? → No demonstrated reduction in cancer risk vs. PPI; reserve for refractory GERD.

Pattern 11 — Chemoprevention: Asymptomatic BE patient asks about aspirin. Best response? → Use only if CV indication; don't initiate solely for BE.

Pattern 12 — Bariatric in BE: Obese BE patient considering bariatric surgery. Recommend? → Roux-en-Y, not sleeve gastrectomy.

One-Line Recap

Barrett esophagus is intestinal metaplasia of the distal esophagus that requires risk-factor–driven screening, lifelong PPI plus interval EGD surveillance, and endoscopic eradication therapy (EMR for visible lesions + RFA) for any confirmed dysplasia — with intensity calibrated to histology, segment length, comorbidities, and life expectancy.

High-yield recap bullets:

Board pearl: Master three things and most BE Step 3 questions fall: (1) who to screen, (2) the histology-to-interval grid, and (3) EMR before RFA for any visible lesion. Add the lifestyle/PPI longitudinal plan and the elderly de-escalation logic, and the topic is high-yield complete.

Screen, don't surveil indiscriminately: Offer one-time EGD only to GERD patients with multiple risk factors (chronic GERD, male, white, age >50, smoker, central obesity, family history); irregular Z-line <1 cm is not BE.

Histology drives management: NDBE → EGD every 3 yrs (long) or 5 yrs (short); confirmed LGD → preferred EET (RFA) vs. q6-mo surveillance; HGD/T1a → EET with EMR of nodules first, ablate to CE-IM, then post-EET surveillance schedule (3, 6, 12 mo, then annual).

Pharmacotherapy and chemoprevention: Once-daily PPI for all (BID if symptomatic or post-EET); don't stop PPI for unproven long-term risks; aspirin only if independent CV indication; Nissen fundoplication controls reflux but does not prevent EAC.

Step 3 longitudinal lens: Track waist, weight, smoking, PPI adherence, and next EGD date at every visit; deploy shared decision-making to discontinue surveillance when life expectancy <5–10 years; protect against loss to follow-up at care transitions — the most common preventable cause of interval cancers.